Clinical Research Papers:
Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
Metrics: PDF 1175 views | HTML 2064 views | ?
Jian Zhang1,*, Minhao Fan1,*, Jie Xie1, Zhonghua Wang1, Biyun Wang1, Sheng Zhang1, Leiping Wang1, Jun Cao1, Zhonghua Tao1, Ting Li1, Xichun Hu1
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
*These authors have contributed equally to this work
Xi-chun Hu, e-mail: [email protected]
Keywords: platinums, metastatic breast cancer, triple-negative, chemotherapy
Received: July 09, 2015 Accepted: September 21, 2015 Published: October 03, 2015
The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference of OS was observed. Compared with other kinds of platinum, cisplatin-based regimens as the first-line chemotherapy showed better PFS (8.0 vs. 4.3 months, P = 0.03) and better ORR. Introduction of ≥2 lines, rather than 1 line, of PBCT can result in better OS when compared with no introduction of PBCT during the whole treatment. If considering the timing of intervention of PBCT, first-line introduction and later line introduction of PBCT did not make any difference in OS among patients with only one line PBCT during the whole treatment. We concluded that PBCT with only 1 line during the whole treatment might not be necessary for unselected mTNBC with the exception of an urgent demand to control disease or symptoms, however, ≥2 lines of PBCT did prolong OS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.